MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Primary Care, Chronic Disease, Wellness, Weight Loss, Obesity, Coordinated Care
2021: Portfolio Roundup: 30 Startups Tackling Chronic Disease_healthtransformer.co
PatientWing
*Industry: Philadephia, Pennsylvania
CARISMA Therapeutics
Organization & Developments: Eleven Biotherapeutics
Parents
CARISMA Therapeutics
CARISMA Therapeutics, formerly, Sesen Bio, Inc. (NASDAQ: SESN), formerly, Eleven Biotherapeutics (Nasdaq: EBIO)
Children
*Clinical company focused on advancing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer.
*Investors’ bet they can create genetically engineered protein drugs with greater capability to bind with targets than today’s antibodies
*Quite a few companies have been sprouting up and raising cash in the last couple years with similar notions of developing “bio-superiors” or “bio-betters.” (2010)
2014: Eleven Biotherapeutics shows promise with new drug for eye disease
2016: Eleven Biotherapeutics: What Went Wrong, What Went Right, And How You Can Spot Similar Opportunities In The Future - Eleven Biotherapeutics, Inc. (NASDAQ:EBIO)
2016: January 15, 2016: Eleven Biotherapeutics announces the results of its Phase 3 study of EBI-005 for allergic conjunctivitis. The drug failed to meet its primary end point.
2016: June 13, 2016: Eleven Biotherapeutics announces that it has agreed to grant an exclusive license to F. Hoffmann-La Roche Ltd ("Roche") to develop and commercialize EBI-031
2018: Sesen Bio: Nanocap With Major Catalysts Ahead_seekingalpha.com
2018: Sesen_‘Off The Radar’ ... Biotech Stock Under $2
2019: IBI Research On Sesen: What Investors Can Expect Going Forward?_seekingalpha.com
2020: Sesen Bio: A Look At Vicineum's Potential
2021: FDA declines to approve Sesen Bio's Vicineum bladder cancer treatment
2021: Sesen Bio: Long-Term And Short-Term Potential In Advance Of Its First PDUFA
2021: Sesen Bio: Problems Of Main Competitor Make Vicinium More Attractive
2021: Sesen Bio: Vicineum's Priority Review Provides Conviction To Hold Through PDUFA Date
2021: Sesen: Vicineum Could Be The Ultimate Catalyst
2022: Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives_seekingalpha.com
Jumps
*Key People: Eleven Biotherapeutics
Finance & Acquisitions: Eleven Biotherapeutics